Generation Bio (GBIO) Stock Price

Generation Bio Price

NASDAQ·CLOSED
5.34
​
Market closed

Over the last 6 years Generation Bio grew revenue by 186.5% annually, reaching 19.89 M USD. For Generation Bio, the net margin of -661.9% is up versus -99,452.8% a few years ago. The consensus 12-month price target for Generation Bio is 8.42 USD, about 57.6% above where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.

Generation Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio business model & stock analysis

Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate.

Frequently asked questions about Generation Bio

Analysts currently set an average price target of 8.42 USD for the Generation Bio stock (median: 8.42 USD), implying +57.6 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Generation Bio stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Generation Bio to generate revenue of 3.83 M USD and earnings per share of -3.76 USD.

Converted at the current exchange rate, the Generation Bio share trades at 4.77 EUR (5.34 USD).

The Generation Bio share (GBIO) is listed on 1 stock exchanges, including: NASDAQ (GBIO).

The expected revenue of Generation Bio is 3.83 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Generation Bio is -25.07 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Generation Bio is currently -1.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Generation Bio stock.

The price-to-sales ratio (P/S) of Generation Bio is currently 9.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Generation Bio stock.

The Eulerpool Quality Score for Generation Bio is 3/10.

The ISIN of Generation Bio is US37148K2096. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Generation Bio is A2P5NL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Generation Bio is GBIO. The ticker symbol is used to trade Generation Bio shares on the stock exchange.

Fair ValueTerminal
5.39 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
172,973.91 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 12, 2020
ISIN
US37148K2096
Cusip
37148K100
Sedol
BMC2Z79
Market capitalization
35.99 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.55
P/Ee 2026
-1.42
P/Ee 2027
-2.71
P/Ee 2028
10.08
P/Ee 2029
14.83
P/S
P/Se
3.10
EV/EBIT
0.82
P/B Ratio
0.42
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-152.74 %
Last updated Nov 10, 2026, 11:07 PM

Generation Bio Ticker

NASDAQ · GBIO

All fundamentals and in-depth analysis of Generation Bio

Our stock analysis for Generation Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Generation Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.